Cerus to Present at AABB Symposium on Pathogen-Reduced Components

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) will be presenting today at the AABB Symposium on Implementation of Pathogen-Reduced Blood Components taking place in Bethesda, Maryland from April 27 to 28, 2015.

Cerus’ presentation will address the INTERCEPT Blood System today and its future outlook, including:

• Current FDA approved label claims for INTERCEPT, including the ability to reduce transfusion-transmitted infectious risk in apheresis platelet components, and apheresis or whole blood derived plasma components.
• Key potential blood center operational advantages, such as improved platelet availability and reduced component wastage through early platelet release with pathogen reduction.
• Plans to expand claims to include a seven-day platelet shelf-life extension, the ability to pathogen reduce whole blood derived platelets, and the development of an INTERCEPT triple set storage kit for improved platelet collection efficiency.
• INTERCEPT red cell system developments, including the successful completion of US Phase II and European Phase III trials.

Cerus’ presentation is part of AABB’s overall symposium agenda that will cover considerations on the successful implementation of pathogen reduction for blood collectors and transfusion services. The symposium is being held in light of the recent FDA approvals, as well as a New England Journal of Medicine article released last week in which US key opinion leaders argue for an FDA mandate for pathogen reduction to mitigate residual risks due to bacterial contamination, as well as established and emerging transfusion-transmitted infections.1

In addition to US status and outlook, other presenters during the AABB symposium will cover the extensive European experience with pathogen reduction, including the implementation of INTERCEPT in Switzerland, which involved the installation and validation of the system in 13 blood transfusion centers within 11 months.

For further information about the symposium, visit:

http://www.aabb.org/development/Pages/pathogen-reduction-symposium.aspx.

1. Snyder EL, Stramer SL, Benjamin RJ. N Engl J Med. 2015 Apr 22, Epub ahead of print.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for information about Cerus.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to operational advantages and ability to improve the timing of release for platelet products; the uncertain and time-consuming development and regulatory process, including risks related to Cerus‘ ability to expand the label claims for THE INTERCEPT platelet systems in the U.S. and potential expanded label claims for the INTERCEPT platelet systems in the U.S.. These forward-looking statements are based upon Cerus’ current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with the uncertainty of future clinical trial results, the uncertain and time-consuming regulatory process; and other risks detailed in Cerus' filings with the SEC, including Cerus' annual report on Form 10-K filed with the SEC on March 16, 2015. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

Investor Relations Contact:
Cerus Corporation
Lainie Corten, 925-288-6319
VP, Global Marketing & Investor Relations
Media Contact:
W2O Group
Dan Boyle, 818-209-1692

Source: Cerus Corporation

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• B. Riley Financial (RILY) Files 10-K
• Bakkt Holdings, Inc. (BKKT) Announces 1:25 Reverse Share Split